Clinical approach in the management of oral chronic graft-versus-host disease (cGVHD) in a series of specialized medical centers

Supportive Care in Cancer

Volumn 23, Issue 6, 2015, Pages 1615-1622

  Elad, Sharon ^a,b   Jensen, Siri Beier ^c   Raber Durlacher, Judith E ^d,e   Mouradian, Nancy ^a   Correa, Elvira M P ^f   Schubert, Mark M ^g,h,i   Blijlevens, Nicole M A ^j   Epstein, Joel B ^k,l   Saunders, Deborah P ^m   Waltimo, Tuomas ⁿ   Yarom, Noam ^o,p   Zadik, Yehuda ^q,r   Brennan, Michael T ^s  

^a UNIVERSITY OF ROCHESTER   (United States)

^b STRONG MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f UNIVERSITY OF CAMPINAS   (Brazil)

^g USA   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ SEATTLE CANCER CARE ALLIANCE   (United States)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k CEDARS SINAI MEDICAL CENTER   (United States)

^l CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^m HEALTH SCIENCES NORTH   (Canada)

ⁿ UNIVERSITY OF BASEL   (Switzerland)

^o SHEBA MEDICAL CENTER   (Israel)

^p TEL AVIV UNIVERSITY   (Israel)

^q MEDICAL CORPS   (Israel)

^r HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^s CAROLINAS MEDICAL CENTER   (United States)

more..

Author keywords

NIH scale; Oral cancer; Oral care; Oral chronic graft versus host disease; Oral mucosa; Salivary glands; Topical treatment

Indexed keywords

CHRONIC DISEASE; GRAFT VS HOST DISEASE; HOSPITAL; HUMAN; MIDDLE AGED; MOUTH DISEASES; QUESTIONNAIRE;

CHRONIC DISEASE; GRAFT VS HOST DISEASE; HOSPITALS, SPECIAL; HUMANS; MIDDLE AGED; MOUTH DISEASES; QUESTIONNAIRES;

EID: 84939998852     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2503-x     Document Type: Article

References (45)

1. Socie G, Ritz J (2014) Current issues in chronic graft-versus-host disease. Blood 124(3):374–384
2. Blazar BR, Murphy WJ, Abedi M (2012) Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 12(6):443–458
3. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945–956
4. Schubert MM, Correa ME (2008) Oral graft-versus-host disease. Dent Clin North Am 52(1):79–109, viii-ix
5. Kuten-Shorrer M, Woo SB, Treister NS (2014) Oral graft-versus-host disease. Dent Clin North Am 58(2):351–368
6. Daikeler T, Mauramo M, Rovo A, Stern M, Halter J, Buser A et al (2013) Sicca symptoms and their impact on quality of life among very long-term survivors after hematopoietic SCT. Bone Marrow Transplant 48(7):988–993
7. Treister NS, Cook EF Jr, Antin J, Lee SJ, Soiffer R, Woo SB (2008) Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 14(1):110–115
8. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW et al (2006) Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response criteria working group report. Biol Blood Marrow Transplant 12(3):252–266
9. Schubert MM, Sullivan KM (1990) Recognition, incidence, and management of oral graft-versus-host disease. NCI Monogr 9:135–143
10. Garcia FVMJ, Pascual-Lopez M, Elices M, Dauden E, Garcia-Diez A, Fraga J (2002) Superficial mucoceles and lichenoid graft versus host disease: report of three cases. Acta Derm Venereol 82(6):453–455
11. Mays JW, Fassil H, Edwards DA, Pavletic SZ, Bassim CW (2013) Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis 19(4):327–346
12. Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J et al (2006) Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 12(4):375–396
13. Mawardi H, Elad S, Correa ME, Stevenson K, Woo SB, Almazrooa S et al (2011) Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant 46(6):884–891
14. Treister N, Duncan C, Cutler C, Lehmann L (2012) How we treat oral chronic graft-versus-host disease. Blood 120(17):3407–3418
15. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C et al (2012) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 47(3):337–341
16. Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK (1992) Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 69(10):2469–2477
17. Meier JK, Wolff D, Pavletic S, Greinix H, Gosau M, Bertz H et al (2011) Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clin Oral Investig 15(2):127–139
18. Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, Jackson G et al (2012) Organ-specific management and supportive care in chronic graft-versus-host disease. Br J Haematol 158(1):62–78
19. McCormack HM, Horne DJ, Sheather S (1988) Clinical applications of visual analogue scales: a critical review. Psychol Med 18(4):1007–1019
20. Elad S, Zeevi I, Finke J, Koldehoff M, Schwerdtfeger R, Wolff D et al (2012) Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide—an open, randomized, multicenter study. Biol Blood Marrow Transplant 18(1):134–140
21. Park AR, La HO, Cho BS, Kim SJ, Lee BK, Rhie JY et al (2013) Comparison of budesonide and dexamethasone for local treatment of oral chronic graft-versus-host disease. Am J Health Syst Pharm 70(16):1383–1391
22. Noce CW, Gomes A, Shcaira V, Correa ME, Moreira MC, Silva Junior A et al (2014) Randomized double-blind clinical trial comparing clobetasol and dexamethasone for the topical treatment of symptomatic oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 20(8):1163–1168
23. Sari I, Altuntas F, Kocyigit I, Sisman Y, Eser B, Unal A et al (2007) The effect of budesonide mouthwash on oral chronic graft versus host disease. Am J Hematol 82(5):349–356
24. Fortune K, Couriel D (2009) Tacrolimus in hematopoietic stem cell transplantation. Expert Opin Drug Metab Toxicol 5(7):835–841
25. Mawardi H, Stevenson K, Gokani B, Soiffer R, Treister N (2010) Combined topical dexamethasone/tacrolimus therapy for management of oral chronic GVHD. Bone Marrow Transplant 45(6):1062–1067
26. Brown RS, Edwards D, Walsh-Chocolaad T, Childs RW (2013) Topical tacrolimus with custom trays in the treatment of severe oral chronic graft-versus-host disease refractory to a potent topical steroid therapy: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 115(4):e26–e30
27. Eckardt A, Starke O, Stadler M, Reuter C, Hertenstein B (2004) Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol 40(8):811–814
28. Fricain JC, Sibaud V, Swetyenga N, Tabrizi R, Campana F, Taieb A (2007) Long-term efficacy of topical tacrolimus on oral lesions of chronic graft-versus-host disease. Br J Dermatol 156(3):588–590
29. Conrotto D, Broccoletti R, Carcieri P, Giaccone L, Arduino PG (2014) Topical tacrolimus and periodontal therapy in the management of a case of oral chronic GVHD characterized by specific gingival localization. Case Rep Dent 2014:127219
30. 2 laser in oral graft-versus-host disease: a pilot study. Bone Marrow Transplant 32(10):1031–1034
31. Nozaki-Taguchi N, Shutoh M, Shimoyama N (2008) Potential utility of peripherally applied loperamide in oral chronic graft-versus-host disease related pain. Jpn J Clin Oncol 38(12):857–860
32. Singhal S, Powles R, Treleaven J, Rattenbury H, Mehta J (1997) Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. Leuk Lymphoma 24(5–6):539–543
33. Nagler RM, Nagler A (1999) Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study. Bone Marrow Transplant 23(10):1007–1011
34. Agha-Hosseini F, Mirzaii-Dizgah I, Ghavamzadeh L, Ghavamzadeh A, Tohidast-Acrad Z (2007) Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant 39(7):431–434
35. Carpenter PA, Schubert MM, Flowers ME (2006) Cevimeline reduced mouth dryness and increased salivary flow in patients with xerostomia complicating chronic graft-versus-host disease. Biol Blood Marrow Transplant 12(7):792–794
36. Castellarin P, Stevenson K, Biasotto M, Yuan A, Woo SB, Treister NS (2012) Extensive dental caries in patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 18(10):1573–1579
37. Epstein JB, Gorsky M, Fischer D, Gupta A, Epstein M, Elad S (2007) A survey of the current approaches to diagnosis and management of oral premalignant lesions. J Am Dent Assoc 138(12):1555–1562, quiz 614
38. Atsuta Y, Suzuki R, Yamashita T, Fukuda T, Miyamura K, Taniguchi S et al (2014) Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. Ann Oncol 25(2):435–441
39. Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM et al (2011) Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 117(1):316–322
40. Kruse AL, Gratz KW (2009) Oral carcinoma after hematopoietic stem cell transplantation—a new classification based on a literature review over 30 years. Head Neck Oncol 1:29
41. Elad S, Zadik Y, Zeevi I, Miyazaki A, de Figueiredo MA, Or R (2010) Oral cancer in patients after hematopoietic stem-cell transplantation: long-term follow-up suggests an increased risk for recurrence. Transplantation 90(11):1243–1244
42. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB et al (1997) Solid cancers after bone marrow transplantation. N Engl J Med 336(13):897–904
43. Elad S, Zeevi I, Or R, Resnick IB, Dray L, Shapira MY (2010) Validation of the National Institutes of Health (NIH) scale for oral chronic graft-versus-host disease (cGVHD). Biol Blood Marrow Transplant 16(1):62–69
44. Treister NS, Stevenson K, Kim H, Woo SB, Soiffer R, Cutler C (2010) Oral chronic graft-versus-host disease scoring using the NIH consensus criteria. Biol Blood Marrow Transplant 16(1):108–114
45. Bassim CW, Fassil H, Mays JW, Edwards D, Baird K, Steinberg SM et al (2014) Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures. Bone Marrow Transplant 49(1):116–121